Publicación:
Eficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori.

Vista sencilla de ítem
dc.contributor.authorYepes Barreto, Ismael de Jesússpa
dc.contributor.authorOsorio Marín, Claudiaspa
dc.contributor.authorMúnera Contreras, María Nicolspa
dc.date.accessioned2016-07-15 00:00:00
dc.date.available2016-07-15 00:00:00
dc.date.issued2016-07-15
dc.format.mimetypeapplication/pdfspa
dc.identifier.doi10.32997/rcb-2016-2854
dc.identifier.eissn2389-7252
dc.identifier.issn2215-7840
dc.identifier.urlhttps://doi.org/10.32997/rcb-2016-2854
dc.language.isospaspa
dc.publisherUniversidad de Cartagenaspa
dc.relation.bitstreamhttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/2854/2397
dc.relation.citationeditionNúm. 2 , Año 2016spa
dc.relation.citationendpage264
dc.relation.citationissue2spa
dc.relation.citationstartpage258
dc.relation.citationvolume7spa
dc.relation.ispartofjournalRevista Ciencias Biomédicasspa
dc.relation.referencesHunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van-der-Merwe S, Vaz-Coelho LG, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011; 20(3): 299-304.spa
dc.relation.referencesMartinez JD, Henao S, Lizarazo JI. Resistencia antibiótica del Helicobacter pylori en América Latina y el Caribe. Rev Col Gastroenterol. 2014; 29(3): 217-26.spa
dc.relation.referencesBravo LE, Cortes A, Carrascal E, Jaramillo R, García LS, Bravo PE. et al. Helicobacter pylori: patología y prevalencia en biopsias gástricas en Colombia. Colombia médica. 2003; 34(3): 124-31.spa
dc.relation.referencesDe-Armas-Daza L. Prevalencia de Helicobacter pylori según el resultado de la prueba de ureasa rápida y su asociación con alteraciones de la mucosa gástrica en pacientes que asistieron a realizarse endoscopia en cuatro consultorios médicos de Valledupar durante el año 2007: Universidad Nacional de Colombia; 2011. http://www.bdigital.unal.edu.co/7012/1/597673.2011.pdfspa
dc.relation.referencesOtero W, Otero LP, Vallejo MT, Torres-Amaya M, Pardo R, Sabbagh L. Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Col Gastroenterol. 2015; 30: 45-52.spa
dc.relation.referencesCamargo MC, Garcia A, Riquelme A, Otero W, Camargo CA, Hernández-García T, Candia R, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014; 109(4): 485-95. https://doi.org/10.1038/ajg.2014.24spa
dc.relation.referencesAl-Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication--the influence of structured counselling and follow-up. Br J Clin Pharmacol. 2002; 53(2): 163-71. https://doi.org/10.1046/j.0306-5251.2001.01531.xspa
dc.relation.referencesZullo A, De-Francesco V, Hassan C. Predicting Helicobacter pylori eradication: how to teach an old dog new tricks. J Clin Gastroenterol. 2012; 46(4): 259-61. https://doi.org/10.1097/MCG.0b013e318247177espa
dc.relation.referencesHarb AH, Chalhoub JM, Abou Mrad R, Sharara AI. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2015; 42(2): 131-41. https://doi.org/10.1111/apt.13259spa
dc.relation.referencesBago J, Galovic A, Belosic Halle Z, Bilic A, Bevanda M, Bago P. Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. Wien Klin Wochenschr. 2004; 116(14): 495-99. https://doi.org/10.1007/BF03040946spa
dc.relation.referencesAsaka M, Sugiyama T, Kato M, Satoh K, Kuwayama H, Fukuda Y, Fujioka T, et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter. 2001; 6(3): 254-61. https://doi.org/10.1046/j.1523-5378.2001.00037.xspa
dc.relation.referencesBigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther. 1998; 12(4): 383-8. https://doi.org/10.1046/j.1365-2036.1998.00315.xspa
dc.relation.referencesHassan C, De Francesco V, Zullo A, Scaccianoce G, Piglionica D, Ierardi E, Panella C, et al. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment Pharmacol Ther. 2003; 18(6): 641-6. https://doi.org/10.1046/j.1365-2036.2003.01694.xspa
dc.relation.referencesEllenrieder V, Fensterer H, Waurick M, Adler G, Glasbrenner B. Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1998; 12(7): 613-8. https://doi.org/10.1046/j.1365-2036.1998.00354.xspa
dc.relation.referencesChoi IJ, Jung HC, Choi KW, Kim JH, Ahn DS, Yang US, Rew JS, et al. Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2002; 16(1): 145-51. https://doi.org/10.1046/j.1365-2036.2002.01130.xspa
dc.relation.referencesChey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007; 102(8): 1808-25. https://doi.org/10.1111/j.1572-0241.2007.01393.xspa
dc.relation.referencesMalfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, et al. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut. 2012; 61(5): 646-64. https://doi.org/10.1136/gutjnl-2012-302084spa
dc.relation.referencesWang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, Zhou XJ. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. World J Gastroenterol. 2014; 20(40): 14973-85. https://doi.org/10.3748/wjg.v20.i40.14973spa
dc.relation.referencesFord AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2004; 18(4): CD003840. https://doi.org/10.1002/14651858.CD003840.pub2spa
dc.relation.referencesZullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010; 8(2): 105-10. https://doi.org/10.1016/j.cgh.2009.07.017spa
dc.relation.referencesMa JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012; 104(6): 488-92. https://doi.org/10.1093/jnci/djs003spa
dc.relation.referencesBravo LE, Garcia LS, Collazos PA. Cancer survival in Cali, Colombia: A population-based study, 1995-2004. Colomb Med. 2014; 45(3): 110-16. https://doi.org/10.25100/cm.v45i3.1525spa
dc.relation.referencesChatenoud L, Bertuccio P, Bosetti C, Malvezzi M, Levi F, Negri E, La Vecchia C. Trends in mortality from major cancers in the Americas: 1980-2010. Ann Oncol. 2014; 25(9): 1843-53. https://doi.org/10.1093/annonc/mdu206spa
dc.relation.referencesGong Y, Li Y, Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015; 8(4): 6530-43.spa
dc.relation.referencesSuzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, Sato S, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006; 119(3): 217-24. https://doi.org/10.1016/j.amjmed.2005.10.003spa
dc.relation.referencesIsaza C, Henao J, Martínez JH, Sepulveda Arias JC, Beltrán L. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC Clin Pharmacol. 2007; 7:6. https://doi.org/10.1186/1472-6904-7-6spa
dc.relation.referencesBravo-Villalta HV, Yamamoto K, Nakamura K, Baya A, Okada Y, Horiuchi R. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur J Clin Pharmacol. 2005; 61(3): 179-84. https://doi.org/10.1007/s00228-004-0890-5spa
dc.relation.referencesMegraud F, Coenen S, Versporten A, Kist M, López-Brea M, Hirschl AM, Andersen LP, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013; 62(1): 34-42. https://doi.org/10.1136/gutjnl-2012-302254spa
dc.relation.referencesTveit AH, Bruce MG, Bruden DL, Morris J, Reasonover A, Hurlburt DA, Hennessy TW, et al. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J Clin Microbiol. 2011; 49(10): 3638-43. https://doi.org/10.1128/JCM.01067-11spa
dc.rightsRevista Ciencias Biomédicas - 2016spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.creativecommonsEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.sourcehttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/2854spa
dc.subjectInfección por Helicobacterspa
dc.subjectGastroenterologíaspa
dc.subjectEndoscopia del sistema digestivospa
dc.subjectHelicobacter infectionseng
dc.subjectGastroenterologyeng
dc.subjectEndoscopy digestive systemeng
dc.titleEficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori.spa
dc.title.translatedEfficacy and determining factors of the response to treatment with clarithromycin, esomeprazol and amoxacylin for H. Pylori infection.eng
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.localJournal articleeng
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublication

Archivos

Colecciones

Revista Ciencias Biomédicas - Portal de Revistas

Datos de Contacto

Imagen Escudo Universidad de Cartagena

 

 

 

Sede: Claustro de San Agustín, Centro Histórico, Calle de la Universidad Cra. 6 #36-100
Colombia, Bolívar, Cartagena
Ver más...

Línea de Atención

Línea Anticorrupción

Síguenos en: